Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of ...

We learned that Smokey X was diagnosed with a type of kidney cancer. He is not the first in the long line of hounds to get a diagnosis like this.

Apellis expects EMPAVELI launch metrics to be measured by patient start forms, projecting 225 cumulative start forms or more by the end of 2025. Management reiterated, "We believe we have worked ...

To the untrained eye, Viking Creek is easy to overlook. Hemmed in by the busy boulevard connecting downtown Whitefish to its ...

Following that super-limited run of 25 Murphy Lab replicas, the Ebony P-90-equipped Les Paul Standard Noel Gallagher played ...

The first airplane to move faster than the speed of sound — or 767 mph — took off nearly 80 years ago in 1947, according to ...

Scan, the company's toilet-mounted health sensor first unveiled at CES 2023, is now available in both the U.S. and Europe ...

Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded ...

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® ...